PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : A61K 9/20, 31/505, 9/50

A1

(11) International Publication Number: **WO 00/24383**

(43) International Publication Date: 4 May 2000 (04.05.00)

(21) International Application Number: PCT/IB99/01619

(22) International Filing Date: 4 October 1999 (04.10.99)

(30) Priority Data:

9823192.1	23 October 1998 (23.10.98)	GB
9826392.4	27 October 1998 (27.10.98)	GB
9825117.6	16 November 1998 (16.11.98)	GB

(71) Applicant *(for all designated States except GB JP US)*: PFIZER RESEARCH AND DEVELOPMENT COMPANY, N.V./S.A. [BE/IE]; La Touche House, International Financial Services Centre, Dublin 1 (IE).

(71) Applicant *(for JP only)*: PFIZER INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US).

(71) Applicant *(for GB only)*: PFIZER LIMITED [GB/GB]; Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: KING, Elizabeth [GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). MACRAE, Ross, James [GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).

(74) Agent: SPIEGEL, Allen, J.; Pfizer Inc., 235 East 42nd Street, New York, NY 10017 (US).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

(54) Title: CONTROLLED–RELEASE PHARMACEUTICAL FORMULATIONS CONTAINING A CGMP PDE–5 INHIBITOR

(57) Abstract

The invention provides controlled–release formulations for oral adminstration containing a cGMP PDE–5 inhibitor. The formulations are useful, *inter alia*, in the treatment or prevention of sexual dysfunction.